His main research concerns Dendrimer, Drug delivery, Pharmacology, Drug carrier and Microglia. Rangaramanujam M. Kannan carries out multidisciplinary research, doing studies in Dendrimer and Linker. His research in Drug delivery intersects with topics in Biophysics, Intracellular and Drug.
His work deals with themes such as Systemic administration, Biodistribution, Pathology, Thymidine and Cytotoxicity, which intersect with Pharmacology. His Microglia research is multidisciplinary, incorporating perspectives in Surgery, Macular degeneration, Rabbit model, Neuroinflammation and Multiple sclerosis. His work on Nanotoxicology and Nanodevice as part of general Nanotechnology study is frequently linked to Design elements and principles and Structure control, bridging the gap between disciplines.
Rangaramanujam M. Kannan mainly focuses on Dendrimer, Microglia, Neuroinflammation, Pharmacology and Drug delivery. His study in Dendrimer is interdisciplinary in nature, drawing from both Cancer research, Glioblastoma, In vitro, Nanotechnology and Biophysics. His Microglia study integrates concerns from other disciplines, such as Cell biology, Neuroscience, Neuroprotection and Blood–brain barrier.
His research integrates issues of Systemic administration, Pathogenesis and Targeted drug delivery in his study of Neuroinflammation. The Pharmacology study combines topics in areas such as Glutamate receptor, Excitotoxicity, Retinal and Surgery. His Drug delivery research includes elements of Flow cytometry and Drug.
His primary scientific interests are in Dendrimer, Microglia, Neuroinflammation, Cancer research and Glioblastoma. The various areas that Rangaramanujam M. Kannan examines in his Dendrimer study include Acetylcysteine, Combinatorial chemistry and Pathology. His Microglia research is multidisciplinary, incorporating elements of Central nervous system, Neuroprotection, Pharmacology, Immune system and Cell biology.
His work carried out in the field of Neuroinflammation brings together such families of science as Ischemic retinopathy, Biophysics, Targeted drug delivery, Triamcinolone acetonide and Pathological Angiogenesis. Rangaramanujam M. Kannan focuses mostly in the field of Cancer research, narrowing it down to matters related to Systemic administration and, in some cases, Intracellular, Blood–brain barrier and Brain tumor. His Zebrafish study combines topics in areas such as Drug delivery and Regeneration.
The scientist’s investigation covers issues in Microglia, Neuroinflammation, Dendrimer, Pharmacology and Biophysics. His Microglia research includes themes of Tumor necrosis factor alpha, Ex vivo, Enterocolitis, Neurodegeneration and Programmed cell death. His studies deal with areas such as Systemic administration and Nanocarriers as well as Neuroinflammation.
His Dendrimer research focuses on Central nervous system and how it connects with Glioblastoma, In vitro and Cell biology. Rangaramanujam M. Kannan combines subjects such as Immune system, Stimulation, Peroxisome, Adrenoleukodystrophy and Glutamate secretion with his study of Pharmacology. His work deals with themes such as Targeted drug delivery, Endocytosis, Pinocytosis, Internalization and Flow cytometry, which intersect with Biophysics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications
Anupa R. Menjoge;Rangaramanujam M. Kannan;Rangaramanujam M. Kannan;Donald A. Tomalia.
Drug Discovery Today (2010)
Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers
Parag Kolhe;Ekta Misra;Rangaramanujam M. Kannan;Sujatha Kannan.
International Journal of Pharmaceutics (2003)
The effect of surface functionality on cellular trafficking of dendrimers.
Omathanu P. Perumal;Rajyalakshmi Inapagolla;Sujatha Kannan;Rangaramanujam M. Kannan.
Improvement in ductility of chitosan through blending and copolymerization with PEG: FTIR investigation of molecular interactions
Parag Kolhe;Rangaramanujam M. Kannan.
Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications.
R. M. Kannan;E. Nance;S. Kannan;D. A. Tomalia;D. A. Tomalia.
Journal of Internal Medicine (2014)
Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model
Sujatha Kannan;Hui Dai;Hui Dai;Raghavendra S. Navath;Raghavendra S. Navath;Bindu Balakrishnan;Bindu Balakrishnan.
Science Translational Medicine (2012)
Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery.
Yunus E. Kurtoglu;Raghavendra S. Navath;Raghavendra S. Navath;Bing Wang;Bing Wang;Sujatha Kannan;Sujatha Kannan.
Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload.
Parag Kolhe;Jayant Khandare;Omathanu Pillai;Sujatha Kannan.
Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Sezen Gurdag;Jayant Khandare;Sarah Stapels;Larry H. Matherly.
Bioconjugate Chemistry (2006)
Synthesis, Cellular Transport, and Activity of Polyamidoamine Dendrimer−Methylprednisolone Conjugates
Jayant Khandare;Parag Kolhe;Omathanu Pillai;Sujatha Kannan.
Bioconjugate Chemistry (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: